Compass pathways stock forecast.

According to 11 analyst offering 12-month price targets in the last 3 months, Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00.WebAccording to COMPASS Pathways's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.54468. At the end of 2022 ...COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. …

47.29. -1.64%. 4.73M. Find the latest Compass Pathways Plc (CMPS) stock forecast, 12-month price target, predictions and analyst recommendations.WebNov 11, 2021 · Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ... On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.

Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis.

17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.CMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)Jul 1, 2023 · While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months. Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ...

We explain how to buy Compass Pathways Plc stock, compare the best stock trading platforms and use a detailed analysis to learn about (CMPS).

COMPASS Pathways-stock; ... Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00. ... Some analysts will also offer forecasts for metrics like growth ...

Compass Pathways Plc - ADR Stock Price Forecast, "CMPS" Predictons for2023. Markets; Forecast . Crypto Forecasts; Top 5 Crypto forecasts; Tether Usdt forecast; ... Compass Pathways Plc - ADR Stock Forecast and Price Prognosis Data for 2023 . History; Forecast; Data; Market; Q&A; Comments; Buy CRYPTOCOMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $38.00... EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research ...10 stocks we like better than Compass Pathways Plc When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).Compass Pathways (NASDAQ: CMPS) is owned by 35.95% institutional shareholders, 57.27% Compass Pathways insiders, and 6.79% retail investors. Ekaterina Malievskaia is the largest individual Compass Pathways shareholder, owning 12.82M shares representing 20.71% of the company. Ekaterina Malievskaia's Compass Pathways shares are …

COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range …In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. Nov 11, 2021 · Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...

What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...WebThe COMPASS Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on August [3], 2023. Please register in advance here to access the call and obtain a local or toll-free phone number and personal pin. A live webcast of the call will be available on COMPASS Pathway’s website at: Second Quarter 2023 Financial …

Nov 30, 2023 · Overview Financials Statistics Forecast Profile Chart Forecast Analyst Ratings COMPASS Pathways Stock Forecast All Analysts Top Analysts Stock Price Forecast According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. 10 stocks we like better than COMPASS Pathways When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ...Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebStock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Past 5 Years (per annum) N/A. N/A. N/A. N/A. See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Web

Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Web

COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.Web

These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024.(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...WebCash position at 30 June 2022 of $207.2 million. Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a …Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebThe 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC.Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...WebCompass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed ...We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.Web

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.WebAbout CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.In the last 3 months, 4 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $53.75 with a high of $120.00 and a low of $19.00.Instagram:https://instagram. short selling forexbest paying annuitiesbest performing international etfschd ex dividend Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ... nyse aubwhatsapp login with email First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in …Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.Web why is nvidia stock falling Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...WebCOMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a …